Nextcure announces development of a highly specific immunohistochemical diagnostic for siglec-15-positive tumors as reported in laboratory investigation

Beltsville, md., july 06, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “development of an immunohistochemical assay for siglec-15” in laboratory investigation. the publication outlines data from a study, conducted in collaboration with researchers in the department of pathology at yale school of medicine, utilizing a newly developed antibody to siglec-15 (s15) and an immunhistochemical (ihc) assay to investigate s15 expression in solid tumors.
NXTC Ratings Summary
NXTC Quant Ranking